Stifel Nicolaus Remains a Buy on Zoetis (ZTS)

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Zoetis (ZTSResearch Report) on June 24 and set a price target of $225.00. The company’s shares closed last Friday at $174.61.

According to, Block is a 5-star analyst with an average return of 13.8% and a 58.0% success rate. Block covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Idexx Laboratories, and Envista Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zoetis with a $219.60 average price target, which is a 27.7% upside from current levels. In a report issued on June 17, Argus Research also maintained a Buy rating on the stock with a $200.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $249.27 and a one-year low of $154.18. Currently, Zoetis has an average volume of 2.25M.

Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZTS in relation to earlier this year. Most recently, in April 2022, Roxanne Lagano, the EVP of ZTS sold 2,167 shares for a total of $387,806.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Founded in 1952, New Jersey-based Zoetis, Inc. is the world’s largest manufacturer of medicine and vaccinations for pets and livestock in the United States and internationally. Its products are complemented by diagnostic products, genetic tests, bio devices and services.

Read More on ZTS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More